CNBX Pharmaceuticals Inc. operates as a pharmaceutical company. The Company develops cannabinoid-based antitumor drug candidate for the treatment of colorectal cancer based on novel and proprietary formulation. CNBX Pharmaceuticals serves patients in the United States.

Annual Report (Form 10-K | Period ending 2024-08-31)

Quarterly Report (Form 10-Q | Period ending 2024-05-31)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CNBX Pharmaceuticals (CNBX US)

Annual Report (Form 10-K | Period ending 2024-08-31)

Quarterly Report (Form 10-Q | Period ending 2024-05-31)

Quarterly Report (Form 10-Q | Period ending 2024-02-29)

Current Report (Form 8-K | Period ending 2024-03-18)

General form for quarterly reports under Section 13 or 15(d) (PDF)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)